Literature DB >> 20421519

Mechanism of improved cardiac function after bone marrow mononuclear cell therapy: role of cardiovascular lineage commitment.

Chang-Hwan Yoon1, Masamichi Koyanagi, Kazuma Iekushi, Florian Seeger, Carmen Urbich, Andreas M Zeiher, Stefanie Dimmeler.   

Abstract

BACKGROUND: Cell therapy is a promising option to improve functional recovery after ischemia. Several subsets of bone marrow-derived cells were shown to reduce infarct size and increase ejection fraction in experimental models of ischemia. The mechanisms underlying the functional improvement are diverse and have been shown to include paracrine effects of the injected cells, as well as a variable degree of differentiation to endothelial cells, pericytes, smooth muscle, and cardiac muscle. METHODS AND
RESULTS: To elucidate the true nature of such plasticity and contribution to recovery, we engineered vectors that encoded inducible suicide genes under the control of endothelium (endothelial nitric oxide synthase)-, smooth muscle (SM22alpha)-, and cardiomyocyte (alpha-MHC)-specific promoters, thereby allowing selective depletion of the individual cell lineage acquired by the transplanted undifferentiated bone marrow-derived cells. Lentivirally delivered thymidine kinase, which converts the prodrug ganciclovir into a cytotoxic agent, was used to selectively eliminate cells 2 weeks after transplantation of bone marrow mononuclear cells in an acute myocardial infarction model. We demonstrate that elimination of transplanted endothelium-committed or SM22alpha-expressing cells, but not cardiac-committed cells, induced a significant deterioration of ejection fraction. Moreover, elimination of endothelial nitric oxide synthase-expressing cells 2 weeks after injection reduced capillary and arteriole density.
CONCLUSIONS: This study demonstrates that elimination of bone marrow mononuclear cells reexpressing endothelial nitric oxide synthase particularly induced a deterioration of cardiac function, which indicates a functional contribution of the vascular cell fate decision of human bone marrow-derived mononuclear cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20421519     DOI: 10.1161/CIRCULATIONAHA.109.909291

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  49 in total

1.  Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy.

Authors:  David M Leistner; Ulrich Fischer-Rasokat; Jörg Honold; Florian H Seeger; Volker Schächinger; Ralf Lehmann; Hans Martin; Iris Burck; Carmen Urbich; Stefanie Dimmeler; Andreas M Zeiher; Birgit Assmus
Journal:  Clin Res Cardiol       Date:  2011-06-03       Impact factor: 5.460

Review 2.  Stem cell-based therapies in ischemic heart diseases: a focus on aspects of microcirculation and inflammation.

Authors:  Junxi Wu; Jun Li; Nannan Zhang; Cuihua Zhang
Journal:  Basic Res Cardiol       Date:  2011-03-23       Impact factor: 17.165

Review 3.  Restoring the renal microvasculature to treat chronic kidney disease.

Authors:  David A Long; Jill T Norman; Leon G Fine
Journal:  Nat Rev Nephrol       Date:  2012-02-07       Impact factor: 28.314

Review 4.  Mechanisms of Cardiac Repair and Regeneration.

Authors:  Kathleen M Broughton; Bingyan J Wang; Fareheh Firouzi; Farid Khalafalla; Stefanie Dimmeler; Francisco Fernandez-Aviles; Mark A Sussman
Journal:  Circ Res       Date:  2018-04-13       Impact factor: 17.367

5.  Cardiac cell therapy: the next (re)generation.

Authors:  Elvira Forte; Isotta Chimenti; Lucio Barile; Roberto Gaetani; Francesco Angelini; Vittoria Ionta; Elisa Messina; Alessandro Giacomello
Journal:  Stem Cell Rev Rep       Date:  2011-11       Impact factor: 5.739

6.  Functions of Mesenchymal Stem Cells in Cardiac Repair.

Authors:  Selçuk Öztürk; Ayşe Eser Elçin; Yaşar Murat Elçin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells.

Authors:  Tao-Sheng Li; Ke Cheng; Konstantinos Malliaras; Rachel Ruckdeschel Smith; Yiqiang Zhang; Baiming Sun; Noriko Matsushita; Agnieszka Blusztajn; John Terrovitis; Hideo Kusuoka; Linda Marbán; Eduardo Marbán
Journal:  J Am Coll Cardiol       Date:  2012-03-06       Impact factor: 24.094

Review 8.  Coronary collateral growth--back to the future.

Authors:  William M Chilian; Marc S Penn; Yuh Fen Pung; Feng Dong; Maritza Mayorga; Vahagn Ohanyan; Suzanna Logan; Liya Yin
Journal:  J Mol Cell Cardiol       Date:  2011-12-19       Impact factor: 5.000

Review 9.  Vascular stem cells-potential for clinical application.

Authors:  Sadie C Slater; Michele Carrabba; Paolo Madeddu
Journal:  Br Med Bull       Date:  2016-06       Impact factor: 4.291

Review 10.  Human heart failure: is cell therapy a valid option?

Authors:  Marcello Rota; Annarosa Leri; Piero Anversa
Journal:  Biochem Pharmacol       Date:  2013-11-13       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.